Events and presentations
Genmab’s Virtual Capital Markets Day
Investor Relations Overview
Creating value by turning science into medicine
Our ambition is to develop drug candidates that have the potential to transform cancer treatment. We do so by leveraging the success of our partnered assets and continuing to invest in our novel proprietary pipeline and technology platforms.
By 2025, our vision is that our own product will have transformed cancer treatment and we will have a robust pipeline of next-generation antibodies.
Founded in Copenhagen, Denmark in 1999, Genmab A/S’s ordinary shares are listed on the Nasdaq Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Genmab’s American Depositary Shares issued under the ADR Program are listed in the U.S. on the Nasdaq Global Select Market under the ticker symbol GMAB, and the shares are included in the NASDAQ Biotechnology Index (Nasdaq: NBI).
Search and read Genmab’s most recent and previous financial reports.
See our statements, reports, and other forms submitted to the U.S. Securities and Exchange Commission (SEC).
Corporate Social Responsibility
We are committed to being a sustainable and socially responsible biotech company.
Our passion for innovation is driven by data and rooted in science.
See the results of our innovation that is driven by data.
Our commitment to corporate governance is based on ethics and integrity.
Examine key figures
See snapshots of our balance sheets,
cash flow and other statements
Visit the investor library
Access our financial reports, webcasts, presentations and more
Sign up to receive email alerts with
our latest news